Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.